Welcome to our dedicated page for ALXN news (Ticker: ALXN), a resource for investors and traders seeking the latest updates and insights on ALXN stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ALXN's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ALXN's position in the market.
Alexion Pharmaceuticals reported 2020 financial results, with total revenues reaching $6.069 billion, a 22% rise from 2019. However, GAAP diluted EPS decreased to $2.72 from $10.70 due to $2.053 billion in impairment charges linked to KANUMA. Non-GAAP diluted EPS grew by 19% to $12.51. Total revenues for Q4 were $1.592 billion, up 15% year-over-year. While SOLIRIS and ULTOMIRIS sales increased, KANUMA saw a 14% decline. The company highlighted ongoing clinical trials and a strong pipeline with over 20 development programs.
Alexion Pharmaceuticals (Nasdaq: ALXN) will announce its financial results for Q4 and full year 2020 on February 4, 2021. Due to its acquisition by AstraZeneca, no conference call will be held. The acquisition deal, valued at $39 billion, offers Alexion shareholders $60 in cash and 2.1243 AstraZeneca ADS per share, equating to $175 per share based on AstraZeneca’s stock price at the announcement. The transaction aims to enhance both companies' capabilities in developing medicines and is expected to close in Q3 2021, pending regulatory approvals.
Alexion Pharmaceuticals (NASDAQ: ALXN) has announced a pause in enrollment for its Phase 3 study of ULTOMIRIS in adults with severe COVID-19 on mechanical ventilation, following an independent data monitoring committee's recommendation. The interim analysis showed a lack of efficacy when ULTOMIRIS was added to best supportive care. While patients already enrolled will continue in the study, Alexion plans to analyze the data to identify potential benefit for specific subgroups. The company remains dedicated to the rare disease community and ongoing development of ULTOMIRIS.
Alexion Pharmaceuticals (NASDAQ:ALXN) has achieved significant commercial, clinical, and financial milestones, presenting its strategy at the 39th Annual J.P. Morgan Healthcare Conference. The company targets $9 to $10 billion in revenue by 2025, driven by growth in its neurology franchise and new product launches. Alexion continues to build its innovative pipeline with over 20 programs. The acquisition by AstraZeneca, set to finalize in Q3 2021, promises to enhance its market position and create value for shareholders. The company expects to exceed 2020 revenue guidance of $5.9 to $5.95 billion.
Alexion Pharmaceuticals (Nasdaq: ALXN) will present virtually at the 39th Annual J.P. Morgan Healthcare Conference on January 12 at 7:30 a.m. ET. The event will feature management insights and updates on the company's strategic initiatives.
Live audio webcasts can be accessed at http://ir.alexion.com, and archived versions will be available on the company’s website shortly after the presentation.
AstraZeneca has reached a definitive agreement to acquire Alexion Pharmaceuticals for approximately $39 billion, translating to $175 per share for Alexion shareholders. The deal comprises $60 in cash and 2.1243 AstraZeneca ADSs per Alexion share, representing a premium of 45% over Alexion's closing stock price prior to the announcement. This acquisition, approved by both companies' boards, is anticipated to close in Q3 2021, pending regulatory and shareholder approvals. AstraZeneca aims to enhance its immunology portfolio and leverage Alexion's expertise in rare diseases.
Alexion Pharmaceuticals (NASDAQ:ALXN) announces the European Commission's approval of ULTOMIRIS® 100 mg/mL for treating paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). This long-acting C5 inhibitor reduces average annual infusion times by approximately 60%, lowering treatment time to six hours or less per year. The approval is based on a comprehensive clinical data set confirming comparable safety and efficacy to the original formulation. ULTOMIRIS 100 mg/mL aligns with Alexion's commitment to improve patient quality of life and reduce healthcare burdens.
Alexion Pharmaceuticals (Nasdaq:ALXN) announced its participation in two upcoming investor conferences. The Stifel 2020 Virtual Healthcare Conference will be held on November 17, 2020, from 10:00-10:30 a.m. ET. Additionally, the 3rd Annual Evercore ISI HealthCONx Conference is scheduled for December 1, 2020, from 8:50-9:35 a.m. ET. Live audio webcasts will be accessible on the Alexion investor website, with archived versions available for a limited time after each event.
Caelum Biosciences and Alexion Pharmaceuticals (NASDAQ: ALXN) announced two accepted abstracts for the 62nd American Society of Hematology (ASH) Annual Meeting. Presentations will focus on CAEL-101, an amyloid fibril-targeted therapy, showcasing its safety and efficacy in AL amyloidosis patients. The Phase 2 study indicates promising early organ response. The CARES Phase 3 program is also underway, enrolling approximately 370 patients globally. CAEL-101 aims to improve organ function by targeting amyloid deposits, having received Orphan Drug Designation from the FDA and EMA.
Alexion Pharmaceuticals (NASDAQ:ALXN) will present six abstracts at the 62nd Annual Meeting of the American Society of Hematology from December 5 to 8, 2020. Key findings include a Phase 3 analysis showing ULTOMIRIS® (ravulizumab-cwvz) is safe and effective for patients over 65 with paroxysmal nocturnal hemoglobinuria (PNH). Data will also cover the use of ULTOMIRIS with immunosuppressive therapy and highlight transfusion avoidance in PNH patients. Additionally, an analysis of aHUS patients underscores challenges in diagnosis and long-term disease persistence in untreated individuals.
